Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Liang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8003-0503; OpenAlex author ID A5027992914. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. Last author DOI 10.1097/js9.0000000000003449↗
  2. The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis. Last author DOI 10.1038/s41388-023-02647-0↗
  3. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Last author DOI 10.1002/jcla.24517↗
  4. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.33410↗
  5. Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis Last author DOI 10.21203/rs.3.rs-307202/v1↗
  6. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Last author DOI 10.1038/s41388-020-01407-8↗
  7. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Last author DOI 10.1002/cam4.1957↗
  8. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.2430↗
  9. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.2147/cmar.s197911↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaxiang Xu · 8 shared papers, 2019–2023 · strength 0.91
  2. Wenquan Wang · 7 shared papers, 2019–2026 · strength 0.85
  3. Tianjiao Li · 7 shared papers, 2019–2022 · strength 0.72
  4. Xianjun Yu · 7 shared papers, 2019–2022 · strength 0.72
  5. Heli Gao · 6 shared papers, 2019–2022 · strength 0.61
  6. Wuhu Zhang · 6 shared papers, 2019–2022 · strength 0.61
  7. Shirong Zhang · 4 shared papers, 2019–2023 · strength 0.46
  8. Shuo Li · 5 shared papers, 2019–2021 · strength 0.46
  9. Chuntao Wu · 5 shared papers, 2019–2021 · strength 0.46
  10. Xuan Han · 3 shared papers, 2020–2022 · strength 0.36
  11. Hao Li · 2 shared papers, 2021–2023 · strength 0.30
  12. Hao Li · 3 shared papers, 2019–2021 · strength 0.30
  13. Wei Jin · 2 shared papers, 2019–2023 · strength 0.27
  14. Zhihang Xu · 1 shared paper, 2026 · strength 0.24
  15. Ning Pu · 1 shared paper, 2026 · strength 0.24
  16. Taochen He · 1 shared paper, 2026 · strength 0.24
  17. Huijuan Li · 1 shared paper, 2026 · strength 0.24
  18. Wang Jiang · 2 shared papers, 2020–2021 · strength 0.21
  19. Xian-Jun Yu · 1 shared paper, 2023 · strength 0.18
  20. Quanxing Ni · 2 shared papers, 2019 · strength 0.16
  21. Xu Wang · 1 shared paper, 2022 · strength 0.15
  22. Long‐Yun Ye · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.